News from GlySens

2016
Date
News
11.10.16

GlySens Incorporated Shares Recent Data and Market Insights of the Long Term, Fully Implantable Glucose Monitoring System

Bethesda, MD – November 10, 2016 – GlySens Incorporated executives, Bill Markle and Joseph Lucisano, PhD presented separate findings at the 16th annual Diabetes Technology Society meeting. This conference brings together leading scientific researchers and health care professionals from around the world to focus on applying science and new technologies to the fight against diabetes. The presentation entitled “Market Opportunities and Customer Preference Data for a Fully Implanted Long-Term CGM Solution” was given by Mr. Markle, the Company’s President and CEO, while an “Update of Clinical Experience with a Long-Term Fully Implanted CGM System” was presented by Dr. Lucisano, the Founder and CTO. The clinical update was accompanied with a scientific poster presentation. From the GlySens Presentation Abstract: Joseph Y. Lucisano, PhD GlySens Incorporated Objective: […]
10.04.16

Patient Enrollment and Implantation Procedures Complete for FIGS-2 Trial

San Diego, CA – October 4, 2016 – GlySens Incorporated today announced the successful implantation of the twentieth human subject participating in the Function of Implanted Glucose Sensor 2 (FIGS-2) trial [Clinicaltrials.gov NCT02345967] for people with diabetes in the United States. The FIGS-2 study is a multi-center, long-term assessment of the Eclipse™ ICGM® Sensor. The twentieth participant is an important milestone for the company. “We believe the clinical data will further support our growing confidence in our positive safety profile while enabling our technical team to qualify the system software and complete product development” said Bill Markle, President and CEO of GlySens. The primary objective of the FIGS-2 trial is to verify safety and assess tolerance of a long-term, implanted glucose monitoring sensor. The study […]
07.06.16

GlySens Discusses its Long Term Fully Implantable Glucose Monitoring System at 4th Annual NIH Artificial Pancreas Workshop

Bethesda, MD – July 6, 2016 – GlySens Incorporated’s presentation entitled “Continuous, Long-term, Fully Implanted Glucose Sensor” was discussed today by Dr. Joseph Lucisano, the Company’s founder and CTO, at the “Fourth Artificial Pancreas Workshop.” This event, held at the National Institutes of Health (NIH) campus, is organized in coordination with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Diabetes Mellitus Interagency Coordinating Committee (DIMCC). The aim is to bring together a multi-disciplinary forum to discuss current and potential future challenges of bringing new artificial pancreas (AP) technologies to individuals with diabetes. Dr. Lucisano discussed the GlySens Eclipse™ ICGM® System and its potential for eventual application in an artificial pancreas. From the GlySens Presentation Abstract: Joseph Y. Lucisano, PhD1; David […]
03.14.16

Successful Re-implantation of the Eclipse™ ICGM® Sensor in Sixth Clinical Trial Participant

San Diego, CA – March 14, 2016 – GlySens Incorporated today completed the successful re-implantation of the Eclipse™ ICGM® Sensor in a sixth human subject participating in the Function of Implanted Glucose Sensor 2 (FIGS-2) trial [Clinicaltrials.gov NCT02345967] for people with diabetes in the United States. The FIGS-2 study is a multi-center, long- term assessment of the Eclipse ICGM Sensor. Re-implantation of the sixth participant is a crucial step in the sensor development as participants enroll in a second 12-month, in-vivo trial period. “These new data will support our ongoing signal processing assessments as well as an overall assessment of the long term use-case of our implantable technology,” said Joseph Lucisano, PhD, the Company’s founder and CTO. The primary objective of the FIGS-2 trial is […]
01.05.16

GlySens Incorporated Secures $20M Series D Investment to Advance its Fully Implanted, Long-Term Continuous Glucose Monitoring System

SAN DIEGO, January 5/PRNewswire/ – GlySens Incorporated announced today that it has closed a $20M Series D financing led by prior investors from its Series C round, in addition to significant participation from new investors. “The clinical performance of our fully implanted ICGM® system, now with multiple patients approaching 12 months of in-vivo use, was instrumental in our ability to secure incremental funding on terms highly supportive of the Company’s long term vision and viability,” commented William Markle, President and CEO of GlySens. “Our current clinical trial being conducted in San Diego, under an FDA-approved IDE, is continuing to emphatically demonstrate the viability of the GlySens Eclipse ICGM® system to continuously monitor interstitial glucose in subjects with diabetes for a minimum of 12 months, with […]
Date
News
08.14.15

GlySens Incorporated Secures FDA Approval to Extend Second Generation Fully-Implanted CGM Sensor Evaluation from 6 to 12 Months

SAN DIEGO, August 17/PRNewswire/ – GlySens Incorporated announced today that it has secured FDA approval for extending the current human clinical evaluation of its fully implantable continuous glucose monitoring system (the ICGM® System) from the originally approved six-month duration to the system’s commercially-intended operational duration of twelve months. “We very much appreciate the timely review and approval by FDA of our request to extend the duration of this clinical evaluation, and are grateful for their thoughtful and collaborative working approach,” commented Joseph Lucisano, PhD, Co-Founder and CTO of GlySens. “We have been very encouraged by the human clinical experience with the ICGM® System and are pleased that the results of this testing have been suitable to support extending the trial,” continued Dr. Lucisano. The GlySens […]
04.02.15

GlySens Incorporated Names William Markle Chief Executive Officer

SAN DIEGO, Apr. 2 /PRNewswire/ – GlySens Incorporated announced today that William H. Markle has been selected to join the Company as President and Chief Executive Officer. Mr. Markle succeeds founder and current CEO Joseph Lucisano, PhD, who will continue to lead the Company’s development efforts as Chief Technology Officer. Mr. Markle has distinguished himself in a successful 25-year career in the medical device field and was formerly founder, President, and CEO of GluMetrics, Inc. At GluMetrics, he directed the successful development of continuous real-time sensing technology for intravascular glucose monitoring in the intensive care and operating room environment. Previously, he held senior executive positions in marketing and business development at Tensys Medical and Masimo Corporation, and related positions at Baxter Edwards Critical Care and […]
01.05.15

GlySens Incorporated Secures $12M Series C Investment Proceeds dedicated to advanced product commercialization steps

SAN DIEGO, Jan. 5 /PRNewsire/ – GlySens Incorporated announced today that it has closed a $12 million dollar Series C investment round, which included participation from several new investors as well as a group of returning investors that had previously participated in the Company’s Series B financing. The Company will utilize the proceeds from the new investment to advance the development of its ICGM™ continuous glucose monitoring system for people with diabetes. This system includes a fully implantable sensor, with an intended one-year life, that wirelessly transmits glucose levels continuously to an external receiver for display and logging. The system operates without need for any through-the-skin or skin-attached elements and is expected to offer significant advantages to users, as compared with other glucose monitoring approaches. […]
Date
News
11.24.14

GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health Funding provided to support human clinical evaluation of next generation diabetes monitoring system

SAN DIEGO, Nov. 21, 2014 /PRNewsire/ – GlySens Incorporated announced today that it has been awarded a two-year, two million dollar grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH). The grant is intended to support human clinical evaluation of the GlySens second generation ICGM™ long term implantable glucose monitoring system. Final preparations for launch of the trial are underway, and enrollment is expected to begin before the end of 2014. “We are extremely pleased and grateful to have the support of NIDDK and the NIH as we take these next steps in the development of the GlySens ICGM system,” said Joseph Lucisano, PhD, GlySens President and CEO. “As appreciation continues to […]
07.04.14

GlySens-UCSD collaborative research leads to key findings regarding the viability of long term implanted devices

SAN DIEGO, CA – July 4, 2014 – Important research findings were published today regarding GLYSENS INCORPORATED’s collaborative efforts with Professor David Gough’s Biosensor Research Lab at the University of California, San Diego.  The publication, in the journal Biomaterials, is entitled “Permeability of subcutaneous tissues surrounding long-term implants to oxygen” and was released today on the journal’s website. The research project represented a joint effort between GlySens and Dr. Gough’s UCSD group, and examined important factors that influence the rate of oxygen transport to implanted devices, including the influence of the body’s normal and expected “foreign body response.”  An adequate supply of oxygen from the tissue environment is of vital importance for the viability of many types of long term implants, including long term implanted sensors. The results […]
04.02.14

GlySens Incorporated featured in MedCity News

SAN DIEGO, CA – April 2, 2014 – GLYSENS INCORPORATED is profiled in a feature article in today”s edition of MedCity News by author Karen Heyman, entitled, “No more needles: Startup tests implant that can measure blood sugar for up to a year.” Several times every day, many of the nearly 19 million Americans diagnosed with diabetes have to check their glucose levels. Even though this task can be life-saving, patients are often reluctant to do it regularly. Existing methods are either painful (pricking a finger for a blood sample) or cumbersome (implanted sensors that require frequent replacement).  Joseph Y. Lucisano and David A. Gough believe they have a better way.  They are the co-founders of GlySens Incorporated, and hold 18 monitoring and related technology patents. […]
Date
News
08.28.13

GlySens Incorporated’s recent developments are discussed in a feature story in today’s San Diego Union-Tribune

GlySens Incorporated's recent developments are discussed in a feature story in today’s San Diego Union-Tribune
06.18.13

GlySens named as Finalist in the 2013 San Diego Business Journal Innovation Awards

San Diego, CA – June 18, 2013 – GLYSENS INCORPORATED joined a handful of companies in the Medical Device category honored as finalists in the 2013 San Diego Business Journal Innovation Awards. The awards program was created by the San Diego Business Journal to recognize breakthrough technologies and unique new products developed by San Diego companies in a broad spectrum of industries from medical research to aviation safety and social media to mobile senior care. The finalists in ten categories were honored at a reception held today at the Scripps Institute of Oceanography’s Seaside Pavilion in La Jolla. For further information, see Innovation Awards 2013 SDBJ Supplement.
04.10.13

GlySens Discusses its Long Term Fully Implantable Glucose Monitoring System at NIH Artificial Pancreas Conference

Bethesda, MD – April 10, 2013 – GLYSENS INCORPORATED’S presentation entitled “Long Term, Fully-Implanted, Self-Contained Subcutaneous Glucose Sensor: Results from Clinical Evaluation and Applicability for Closed Loop Systems” was delivered today by Dr. Joseph Lucisano, the Company’s president and CEO, at the “Workshop on Innovation towards an Artificial Pancreas,” held at the National Institutes of Health (NIH).  The April 9-10 workshop, co-sponsored by the NIH, the U.S. Food and Drug Administration (FDA), and the Juvenile Diabetes Research Foundation (JDRF), is bringing together over 175 scientists and clinicians from around the world to discuss the latest developments related to glucose sensors, insulin pumps, algorithms, and medications in the quest to develop an “artificial pancreas” closed-loop automatic glucose control system for people with diabetes. In this context, […]
Date
News
11.08.12

GlySens Presents Results of Human Feasibility Study at the Annual Diabetes Technology Meeting

Burlingame, CA – November 8, 2012 – GLYSENS INCORPORATED presented results today of the recently completed first human feasibility trial of its long term, fully implantable continuous glucose monitoring (ICGM) system.  The trial evaluated the Company’s first generation fully-implanted sensors in six individuals with diabetes for periods of five to six months. The presentation, entitled “Application of the Implantable Continuous Glucose Monitoring System in a Human Subject” was delivered by GlySens’s President and CEO Dr. Joseph Lucisano at a morning session of the twelfth annual meeting of the Diabetes Technology Society. The annual meeting, held this year November 8-10 at the Bethesda North Marriott Hotel & Conference Center, is a premier scientific venue for discussion of diabetes care technology. Last year’s meeting brought together over […]
09.12.12

West Health Investment Fund invests in GlySens

West Health Investment Fund invests in GlySens and RxAnte Startups demonstrate innovative technologies to lower the cost of health care in the treatment of diabetes and medication adherence SAN DIEGO, CA. – Sept. 12, 2012 – The West Health Investment Fund, West Health’s fund focused on lowering health care costs, has announced it participated in the recent venture financings of GlySens, Inc. and RxAnte, Inc., two startup technology companies with innovative technologies that could lower the cost of health care. Financial terms of the investments were not disclosed. “Through targeted external investments in companies focused in advancing cost-effective and cost-saving models of care, West Health can impact the cost of health care in the country,” said Nicholas J. Valeriani, chief executive of West Health.  “These […]
05.01.12

GlySens Incorporated featured in Scientific American

SAN DIEGO, CA – May 1, 2012 – GLYSENS INCORPORATED is featured in the May 2012 issue of Scientific American, in an article entitled “Smart Implantable Devices”. In the article, author Katherine Harmon reports: “A new implantable glucose sensor made by GlySens in San Diego might someday offer millions of diabetics a wireless monitoring system of their own. The device takes near-continuous readings under the skin of a patient’s glucose level- which is then correlated to the level in the blood. The result: far more accurate and more complete information for guiding insulin dosing and timing than can be achieved by testing blood from finger pricks. And because the sensor is implanted, it requires less upkeep than current external monitors.”
No press releases
Date
News
07.29.10

GlySens Incorporated profiled by the San Diego Union-Tribune

SAN DIEGO, CA – July 29, 2010 – GLYSENS INCORPORATED is profiled in a front-page story in today’s San Diego Union-Tribune by Staff Writer Keith Darcé, entitled, “SD company hopes monitor will revolutionize diabetes care.” A small San Diego medical device company and a UCSD scientist believe they’ve come up with the solution to a problem that has long vexed people with diabetes: a device that constantly monitors blood-sugar levels without painful finger pricks or frequent maintenance. GlySens is seeking permission from the Food and Drug Administration to launch a pilot study testing its implanted wireless sensor in about a dozen people with diabetes. The request came after researchers completed trials of the device on animals. On Wednesday, University of California San Diego bioengineering professor […]
07.28.10

GlySens’ Implantable Sensor Capable of Long-term Monitoring of Tissue Glucose in Animals

RESEARCH ARTICLE | BIOENGINEERING AND DIABETES Function of an Implanted Tissue Glucose Sensor for More than 1 Year in Animals David A. Gough, Lucas S. Kumosa, Timothy L. Routh, Joe T. Lin and Joseph Y. Lucisano Sci Transl Med 28 July 2010: Vol. 2, Issue 42, p. 42ra53 Sci. Transl. Med. DOI: 10.1126/scitranslmed.3001148 An implantable sensor capable of long-term monitoring of tissue glucose concentrations by wireless telemetry has been developed for eventual application in people with diabetes. The sensor telemetry system functioned continuously while implanted in subcutaneous tissues of two pigs for a total of 222 and 520 days, respectively, with each animal in both nondiabetic and diabetic states. The sensor detects glucose via an enzyme electrode that is based on differential electrochemical oxygen detection, which reduces the sensitivity of […]
07.28.10

GlySens Incorporated First-Generation Sensor Progress reported in Popular Science

SAN DIEGO, CA – July 28, 2010 – Results achieved with the GLYSENS INCORPORATED first-generation implantable glucose monitoring system are reported by author Lauren Gravitz in an article entitled “Wireless, Implantable Glucose Sensor Could Revolutionize Diabetes Treatment,” in this week’s online edition of Popular Science.   Read more…
Date
News
09.01.09

GlySens Incorporated is recognized as a New California 100 Business Innovator by Golden Capital Network & Hamilton Lane

SAN DIEGO, CA – September 1, 2009 – GLYSENS INCORPORATED has been recognized as a New California 100 Innovative Business by Golden Capital Network and Hamilton Lane. New California 100 businesses are some of the most innovative companies in the state representing California’s commitment to innovation, entrepreneurship, and workforce competitiveness. Endorsed by the California Business, Transportation and Housing Agency, New California 100 companies are recognized for their important contributions to the state economy. Approximately 100 companies throughout the State of California received this recognition from over 400 nominations. New California 100 Businesses will be recognized during a luncheon awards ceremony at 11:45am-1:15 pm on September 22, 2009 at the New California 100 Conference in Sacramento’s Sheraton Grand Hotel. New California 100 Businesses are market leading […]
Date
News
11.14.08

GlySens Presentation Voted Best Submission at the Eighth Annual Diabetes Technology Meeting

Bethesda, MD – November 14, 2008 – GLYSENS INCORPORATED’S presentation entitled “Long-term Results of a Subcutaneous Glucose Sensor in Animals” was selected as the Best Submission at the eighth annual meeting of the Diabetes Technology Society. The annual meeting, held this year November 13-15 at the Bethesda North Marriott Hotel & Conference Center, is a premier scientific venue for discussion of new technology developments related to the care of diabetes. More than 600 scientists and clinicians from 24 countries are in attendance. GlySens’s presentation was selected by the Society’s review committee as the best submission from all submitted abstracts and presentations, announced Dr. David Klonoff, the Society’s President and Chair of the meeting’s Planning Committee, at today’s morning session. A total of 182 abstracts are […]